Calcium channel blockers: Their pharmacologic and therapeutic role in hypertension

American Journal of Cardiovascular Drugs

Volumn 7, Issue SUPPL. 1, 2007, Pages 5-15

  Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; PROPRANOLOL; RAMIPRIL; UNINDEXED DRUG; VERAPAMIL; DIHYDROPYRIDINE;

AFRICAN AMERICAN; ANGINA PECTORIS; ANKLE EDEMA; ATRIOVENTRICULAR BLOCK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FIRST PASS EFFECT; FLUSHING; HALF LIFE TIME; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; META ANALYSIS; MONOTHERAPY; PERIPHERAL EDEMA; PRINZMETAL ANGINA PECTORIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STABLE ANGINA PECTORIS; STROKE; SYMPATHETIC TONE; SYSTEMATIC REVIEW; TACHYCARDIA; AFRICAN; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DRUG INDUCED HEADACHE; FOLLOW UP; HEART ARRHYTHMIA; INOTROPISM; THERAPY EFFECT;

EID: 34247626127     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707001-00002     Document Type: Review

References (120)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15-21; 365 (9455): 217-23
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
3. Kannel WB. Risk stratification: new insights from the Framingham study. Am J Hypertens 2001; 13 (1 Suppl. 1): S3-10
4. Weir MR, Hall PS, Behrens MT, et al. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997 Sep; 30 (3 Pt 1): 422-7
5. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995 Feb; 8 (2): 189-92
6. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000 Sep; 36 (3): 646-61
7. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999 Nov 4; 341 (19): 1447-57
8. Opie LH. Pharmacological differences between calcium antagonists. Eur Heart J 1997 Jan; 18 Suppl. A: A71-9
9. Morel N, Buryi V, Feron O, et al. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol 1998 Nov; 125 (5): 1005-12
10. Norvasc (amlodipine besylate) tablets prescribing information. New York, NY: Pfizer Inc., 2005
11. Krum H. Critical assessment of calcium antagonists. Aust Fam Physician 1997 Jul; 26 (7): 841-5, 847-8
12. DynaCirc (isradipine) prescribing information. Liberty Corner (NJ): Reliant Pharmaceuticals LLC, 2000
13. DynaCirc CR (isradipine) prescribing information. Liberty Corner (NJ): Reliant Pharmaceuticals Inc., 2005
14. Nicardipine hydrochloride capsules prescribing information. Spring Valley (NY): Par Pharmaceutical Inc., 2002
15. Cardene SR (nicardipine hydrochloride) prescribing information. Nutley (NJ): Roche Pharmaceuticals, 2000
16. Adalat CC (nifedipine) prescribing information. West Haven (CT): Bayer Pharmaceuticals Corporation, 2004
17. Sular (nisoldipine) prescribing information. Alpharetta (GA): First Horizon Pharmaceutical Corporation, 2004
18. Cardizem CD (diltiazem HCL) prescribing information. Morrisville (NC): Biovail Pharmaceuticals Inc., 2001
19. Cardizem LA (diltiazem hydrochloride) prescribing information. Bridgewater (NJ): Biovail Pharmaceuticals Inc., 2004
20. Cardizem SR (diltiazem HCL) prescribing information. Morrisville (NC): Biovail Pharmaceuticals Inc., 2001
21. Calan (verapamil hydrochloride tablets) prescribing information. Chicago (IL): G.D. Searle LLC, 2003
22. Calan SR (verapamil hydrochloride) sustained-release oral caplets prescribing information. Chicago (IL): G.D. Searle LLC, 2003
23. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991 Jun; 34 (6): 1838-44
24. Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993 Sep; 348 (3): 332-7
25. Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990 Sep-Oct; 18 (5): 711-9
26. Abernethy DR, Schwartz JB. Pharmacokinetics of calcium antagonists under development. Clin Pharmacokinet 1988 Jul; 15 (1): 1-14
27. Eriksson UG, Lundahl J, Baarnhielm C, et al. Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human. Drug Metab Dispos 1991 Sep-Oct; 19 (5): 889-94
28. Tracy TS, Korzekwa KR, Gonzalez FJ, et al. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 1999 May; 47 (5): 545-52
29. Vogelgesang B, Echizen H, Schmidt E, et al. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. 1984. Br J Clin Pharmacol 2004 Dec; 58 (7): S796-803; discussion S804-6
30. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med 1980 Jun 5; 302 (23): 1269-73
31. Stone PH. Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol 1987 Jan 30; 59 (3): 101B-115B
32. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation 1990 Dec; 82 (6): 1962-72
33. Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999 Feb 15; 83 (4): 507-14
34. Hansen JF, Hagerup L, Sigurd B, et al. Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. Am Heart J 1997 Aug; 134 (2 Pt 2): S48-52
35. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Circulation 1997 May 20; 95 (10): 2380-6
36. Weber MA. Calcium channel antagonists in the treatment of hypertension. Am J Cardiovasc Drugs 2002; 2 (6): 415-31
37. Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta blockers for optimal antianginal therapy. Clin Cardiol 1994 Aug; 17 (8): 415-21
38. Papademetriou V. From hypertension to heart failure. J Clin Hypertens (Greenwich) 2004 Oct; 6 (10 Suppl. 2): 14-7
39. Agabiti-Rosei E, Trimarco B, Muiesan ML, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005 May; 23 (5): 1091-8
40. Bilge AK, Atilgan D, Tukek T, et al. Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. Int J Clin Pract 2005 Mar; 59 (3): 306-10
41. Black HR, Elliott WJ, Weber MA, et al. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001 Nov; 38 (5): 1118-23
42. Granier P, Douste-Blazy MY, Tredez P, et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 39 Suppl. 1: S45-6
43. Takami T, Shigematsu M. Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. Clin Exp Hypertens 2003 Nov; 25 (8): 525-35
44. Wang JG, Li Y. Primary and secondary prevention of stroke by antihypertensive drug treatment. Expert Rev Neurother 2004 Nov; 4 (6): 1023-31
45. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000 Dec 9; 356 (9246): 1955-64
46. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000 Jul 29; 356 (9227): 366-72
47. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Se 10-16; 366 (9489): 895-906
48. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000 Jul 29; 356 (9227): 359-65
49. Klungel OH, Heckbert SR, Longstreth WT Jr, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med 2001 Jan 8; 161 (1): 37-43
50. Staessen JA, Thijs L, Birkenhager WH, et al. Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators. Hypertension 1999 Jun; 33 (6): 1476-7
51. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005 May; 28 (5): 385-407
52. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005 Aug; 46 (2): 386-92
53. Flack JM, Sica DA. Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy. J Clin Hypertens (Greenwich) 2005 Apr; 7 (4 Suppl. 1): 9-14
54. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003 Jul 9; 290 (2): 199-206
55. Falkner B. Differences in blacks and whites with essential hypertension: biochemistry and endocrine. State of the art lecture. Hypertension 1990 Jun; 15 (6 Pt 2): 681-6
56. Morris RC Jr, Sebastian A, Forman A, et al. Normotensive salt sensitivity: effects of race and dietary potassium. Hypertension 1999 Jan; 33 (1): 18-23
57. Cubeddu LX, Aranda J, Singh B, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA 1986 Oct 24-31; 256 (16): 2214-21
58. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990 Aug; 150 (8): 1707-13
59. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998 May; 31 (5): 1088-96
60. Sica D. Calcium channel blockers and the kidney. Clin Cornerstone 2004; 6 (4): 39-52
61. Annual Data Report. Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda (MD): 2006.
62. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989 Oct; 36 (4): 526-36
63. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004 Jun; 65 (6): 1991-2002
64. Cummings DM, Amadio Jr P, Nelson L, et al. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med 1991 Feb; 151 (2): 250-9
65. Gottdiener JS, Reda DJ, Williams DW, et al. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1998 Jul 14; 98 (2): 140-8
66. Hedner T. Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Press 1999; 8 (5-6): 296-9
67. Cobb MM, Johnson D, Gallo J, et al. Large-scale postmarketing surveillance of hypertensive patients treated with verapamil. Am J Ther 1995 Jul; 2 (7): 455-461
68. Bakris G, Sica D, Ram V, et al. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens 2002 Jan; 15 (1 Pt 1): 53-7
69. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003 Apr 23-30; 289 (16): 2073-82
70. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993 Aug 11; 270 (6): 713-24
71. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13; 350 (9080): 757-64
72. Chalmers J. Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials. Clin Exp Hypertens 2004 Oct-Nov; 26 (7-8): 709-19
73. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
74. Black HR. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials. Clin Cornerstone 2004; 6 (4): 53-66
75. Frishman WH. Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs 2007; 7 (Suppl. 1): 17-23
76. Magometschnigg D, Brandt D, Hofmann R, et al. Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril - a multicenter study. Int J Clin Pharmacol Ther 1997 Sep; 35 (9): 389-96
77. Toto RD. Management of hypertensive chronic kidney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich) 2005 Apr; 7 (4 Suppl. 1): 15-20
78. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-9
79. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001 Jul 17; 135 (2): 73-87
80. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-60
81. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002 Nov 20; 288 (19): 2421-31
82. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998 Sep; 54 (3): 889-96
83. Voyaki SM, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001 Mar; 19 (3): 511-9
84. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000 Nov 25; 356 (9244): 1789-94
85. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 Dec 5; 347 (23): 1825-33
86. Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004 Sep; 22 (9): 1641-8
87. Plendil (felodipine) extended-release tablets prescribing information. Wilmington, DE: AstraZeneca, 2003
88. Kloner RA, Vetrovec GW, Materson BJ, et al. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardiol 1998 Jan 15; 81 (2): 163-9
89. Massie BM. The safety of calcium-channel blockers. Clin Cardiol 1998 Dec; 21 (12 Suppl. 2): II12-7
90. Ersoy C, Imamoglu S, Budak F, et al. Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. Indian J Med Res 2004 Nov; 120 (5): 481-8
91. Fodor JG. Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. Cardiovasc Drugs Ther 1997 Jan; 10 Suppl. 3: 873-9
92. Landmark K, Forsman M, Lindberg K, et al. Nitrendipine and mefruside in elderly hypertensives: effects on blood pressure, cardiac output, cerebral blood flow and metabolic parameters. J Hum Hypertens 1995 Apr; 9 (4): 281-5
93. Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens 1994 Apr; 8 (4): 273-8
94. Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999 Mar 22; 159 (6): 551-8
95. Quinones-Galvan A, Pucciarelli A, Ciociaro D, et al. Metabolic effects of combined antihypertensive treatment in patients with essential hypertension. J Cardiovasc Pharmacol 2002 Dec; 40 (6): 916-21
96. Thulin T, Lehtonen A, Dahlof C, et al. Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group. Int J Clin Pharmacol Ther 1999 Jan; 37 (1): 28-33
97. Widimsky J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother 2000 Mar; 1 (3): 515-35
98. Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, et al. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004 Jul; 27 (7): 1688-91
99. Cabezas-Cerrato J, Garcia-Estevez DA, Araujo D, et al. Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril). Metabolism 1997 Feb; 46 (2): 173-8
100. Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995 May 22; 155 (10): 1049-54
101. Opie LH. Calcium channel antagonists. Part IV: side effects and contra-indications drug interactions and combinations. Cardiovasc Drugs Ther 1988 Jul; 2 (2): 177-89
102. Ruschitzka FT, Luscher TF. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Am Heart J 1997 Aug; 134 (2 Pt 2): S31-47
103. Cushman WC, Cohen JD, Jones RP, et al. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998 Jan; 11 (1 Pt 1): 23-30
104. Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000; 9 (2-3): 140-5
105. Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998 Oct; 54 (4): 1283-9
106. Bakris GL, Griffin KA, Picken MM, et al. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997 Oct; 15 (10): 1181-5
107. Rubio-Guerra AF, Trevino-Gomezharper C, Rodriguez-Lopez L, et al. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002; 22 (8): 541-6
108. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005 Jun; 19 (6): 491-6
109. Viskoper RJ, Compagnone D, Dies R, et al. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Curr Ther Res 1997; 58 (6): 343-51
110. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995 Nov; 35 (11): 1060-6
111. Weir MR. The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens 1998 Oct; 11 (10): 163S-169S
112. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003 Nov-Dec; 9 (6): 324-32
113. Nuijten M, Wittenberg W, Kosa J. The cost-effectiveness of Tarka for preventing renal failure in type 2 diabetic patients with hypertension in the US health care setting. Value Health 2003; 6 (6): 334
114. Joyce AT, Pedan A, Girase PS, et al. Economic impact of selected fixed-combination angiotensin-converting enzyme inhibitor/calcium channel blocker anti-hypertensives among patients with diabetes. Value Health 2003; 6 (6): 665
115. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3; 290 (21): 2805-16
116. Mancia G, Cooper-Dehoff RM, Hewkin AC, et al. Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the International Verapamil SR-Trandolapril Study. Am Heart J 2004; 17 (5 Part 2): 116A
117. Jamerson K, Champion A, Zhou Q, et al. Verapamil- and atenolol-based strategies are equally effective in black patients with hypertension and coronary artery disease: a subanalysis of the International Verapamil SR-Trandolapril Study (INVEST). Am J Hypertens 2005; 18 (5 Part 2): 109A
118. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004 Nov; 44 (5): 637-42
119. Cooper-DeHoff RM, Kolloch R, Messerli FH, et al. Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: the International Verapamil/Trandolapril Study. J Am Coll Cardiol 2004; 43 (5) Suppl. A: 1085-197
120. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004 Sep; 17 (9): 793-801